JP2014508150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508150A5 JP2014508150A5 JP2013553969A JP2013553969A JP2014508150A5 JP 2014508150 A5 JP2014508150 A5 JP 2014508150A5 JP 2013553969 A JP2013553969 A JP 2013553969A JP 2013553969 A JP2013553969 A JP 2013553969A JP 2014508150 A5 JP2014508150 A5 JP 2014508150A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- gpbp
- halo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 134
- 125000003545 alkoxy group Chemical group 0.000 claims 67
- 101710014200 CERT1 Proteins 0.000 claims 32
- 102100007999 GPBP1 Human genes 0.000 claims 32
- 101700083692 GPBP1 Proteins 0.000 claims 32
- 125000001475 halogen functional group Chemical group 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 22
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 18
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 16
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 206010038444 Renal failure chronic Diseases 0.000 claims 10
- 201000000522 chronic kidney disease Diseases 0.000 claims 10
- 230000001404 mediated Effects 0.000 claims 10
- -1 nitro, hydroxy Chemical group 0.000 claims 10
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 210000002381 Plasma Anatomy 0.000 claims 8
- 102000025380 C-Reactive Protein Human genes 0.000 claims 7
- 108010074051 C-Reactive Protein Proteins 0.000 claims 7
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 7
- 108090001123 antibodies Proteins 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 206010023230 Joint stiffness Diseases 0.000 claims 2
- 230000036823 Plasma Levels Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 108010045030 monoclonal antibodies Proteins 0.000 claims 2
- 102000005614 monoclonal antibodies Human genes 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 206010008469 Chest discomfort Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- 208000010159 IGA Glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010023232 Joint swelling Diseases 0.000 claims 1
- 210000001179 Synovial Fluid Anatomy 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 230000001771 impaired Effects 0.000 claims 1
- 230000002045 lasting Effects 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161444872P | 2011-02-21 | 2011-02-21 | |
| US61/444,872 | 2011-02-21 | ||
| US201161469945P | 2011-03-31 | 2011-03-31 | |
| US61/469,945 | 2011-03-31 | ||
| US201161473411P | 2011-04-08 | 2011-04-08 | |
| US61/473,411 | 2011-04-08 | ||
| PCT/EP2012/052923 WO2012113785A1 (en) | 2011-02-21 | 2012-02-21 | Methods for treating and diagnosing disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508150A JP2014508150A (ja) | 2014-04-03 |
| JP2014508150A5 true JP2014508150A5 (de) | 2015-04-30 |
| JP5913379B2 JP5913379B2 (ja) | 2016-04-27 |
Family
ID=45768210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553969A Expired - Fee Related JP5913379B2 (ja) | 2011-02-21 | 2012-02-21 | 疾病を治療および診断する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20120213800A1 (de) |
| EP (1) | EP2678360A1 (de) |
| JP (1) | JP5913379B2 (de) |
| CN (2) | CN105148269A (de) |
| AU (1) | AU2012219582A1 (de) |
| MX (1) | MX2013009647A (de) |
| WO (1) | WO2012113785A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015524385A (ja) | 2012-07-02 | 2015-08-24 | フィブロスタティン，エス．エル． | Ｇｐｂｐ−１阻害およびその治療的使用 |
| JP6445802B2 (ja) * | 2014-07-16 | 2018-12-26 | 学校法人慶應義塾 | インフラマソーム活性化制御物質のスクリーニング方法 |
| US20160184274A1 (en) * | 2014-12-31 | 2016-06-30 | Fibrostatin, S.L. | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition |
| CN105061600A (zh) * | 2015-09-05 | 2015-11-18 | 苏州普罗达生物科技有限公司 | 类风湿因子IgA抑制多肽及其应用 |
| GB201721387D0 (en) * | 2017-12-20 | 2018-01-31 | Nordic Bioscience As | Tumstatin assay |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
| EP1144650B1 (de) | 1999-02-24 | 2006-01-25 | Juan Saus | Das goodpasture-antigen bindende protein |
| US7273712B2 (en) * | 2000-12-29 | 2007-09-25 | Reddy Us Therapeutics, Inc. | Methods and compositions for detecting compounds that modulate inflammatory responses |
| US6881547B1 (en) | 2001-01-31 | 2005-04-19 | Juan Saus | Methods and reagents for treating autoimmune disorders |
| US7147855B2 (en) | 2001-12-07 | 2006-12-12 | Juan Saus | GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein |
| US7326768B2 (en) | 2003-02-05 | 2008-02-05 | Juan Saus | Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders |
| AU2007211846B2 (en) * | 2006-02-03 | 2013-05-23 | The University Of Sydney | A method of modulating cellular activity and agents for use therein |
| DE102006052916A1 (de) * | 2006-11-08 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM |
| US9884899B2 (en) * | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| EP2543389A3 (de) * | 2007-08-02 | 2013-04-24 | Gilead Biologics, Inc. | Verfahren und Zusammensetzungen zur Behandlung und Diagnose von Fibrose, Tumorinvasion, Angiogenese und Metastasen |
| EP2245022A4 (de) * | 2008-02-25 | 2012-02-22 | Panmira Pharmaceuticals Llc | Antagonisten von prostaglandin-d2-rezeptoren |
| ES2535258T3 (es) | 2008-07-22 | 2015-05-07 | Fibrostatin, Sociedad Limitada | Proteína de unión al antígeno de Goodpasture y su detección |
| ES2523118T3 (es) * | 2009-11-05 | 2014-11-21 | Fibrostatin, S.L. | Inhibición de GPBP utilizando peptidomiméticos de Q2 |
-
2012
- 2012-02-21 MX MX2013009647A patent/MX2013009647A/es unknown
- 2012-02-21 CN CN201510195237.4A patent/CN105148269A/zh active Pending
- 2012-02-21 AU AU2012219582A patent/AU2012219582A1/en not_active Abandoned
- 2012-02-21 EP EP12706027.5A patent/EP2678360A1/de not_active Withdrawn
- 2012-02-21 WO PCT/EP2012/052923 patent/WO2012113785A1/en active Application Filing
- 2012-02-21 JP JP2013553969A patent/JP5913379B2/ja not_active Expired - Fee Related
- 2012-02-21 US US13/400,831 patent/US20120213800A1/en not_active Abandoned
- 2012-02-21 CN CN2012800097129A patent/CN103403030A/zh active Pending
-
2017
- 2017-04-12 US US15/485,827 patent/US10633455B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508150A5 (de) | ||
| JP4594575B2 (ja) | がんのマーカーとして使用されるアネキシン類及び自己抗体 | |
| JP6941324B2 (ja) | 新規な肝硬変または肝線維症のマーカー | |
| JP2017524130A5 (de) | ||
| US8592170B2 (en) | High molecular weight Ngal as a biomarker for chronic kidney disease | |
| RU2018101257A (ru) | Способ детекции нуклеосом, содержащих гистоновые варианты | |
| JP2008530582A5 (de) | ||
| BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
| WO2010038974A3 (ko) | 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 | |
| Zhang et al. | β-actin as a loading control for plasma-based Western blot analysis of major depressive disorder patients | |
| Ummanni et al. | Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers | |
| Debiec et al. | Nephrotic syndrome: A new specific test for idiopathic membranous nephropathy | |
| CN105988011A (zh) | 一种特发性膜性肾病elisa检测试剂盒及其检测方法 | |
| WO2012105590A1 (ja) | 非アルコール性脂肪肝炎の鑑別マーカー及び当該マーカーを指標とした非アルコール性脂肪肝炎の診断方法 | |
| JP2011511762A5 (de) | ||
| WO2011157905A1 (en) | Polyclonal antibody binding to acetylated hmgb1 | |
| JP2011511271A5 (de) | ||
| JP2012513584A5 (de) | ||
| Palladini et al. | Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia | |
| TWI397687B (zh) | 腎病變相關之生物標記的應用及其中所使用的套組 | |
| BR112019020166A2 (pt) | anticorpo que se liga especificamente a região n-terminal de lisil-trna sintetase exposta na membrana celular | |
| JP5730850B2 (ja) | グルテン誘発性自己免疫疾患の診断 | |
| JP2012515893A5 (de) | ||
| JPWO2021130682A5 (de) | ||
| Lu et al. | Serum proteomic-based analysis for the identification of a potential serological marker for autoimmune hepatitis |